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Context: Low-T3 syndrome is a predictor of poor outcome in patientswith cardiac dysfunction. The
study aimed to assess the short-term effects of synthetic L-T3 replacement therapy in patients with
low-T3 syndrome and ischemic or nonischemic dilated cardiomyopathy (DC).
Design:A total of 20 clinically stable patientswith ischemic (n 12) or nonischemic (n 8)DCwere
enrolled. There were 10 patients (average age 72 yr, range 66–77; median, 25–75th percentile)
who underwent 3-d synthetic L-T3 infusion (study group); the other 10 patients (average age 68 yr,
range 64–71) underwent placebo infusion (control group). Clinical examination, electrocardiog-
raphy, cardiac magnetic resonance, and bio-humoral profile (free thyroid hormones, TSH, plasma
renin activity, aldosterone, noradrenaline, N-terminal-pro-B-Type natriuretic peptide, and IL-6)
were assessed at baseline and after 3-d synthetic L-T3 (initial dose: 20 g/m
2 body surfaced) or
placebo infusion.
Results:After T3 administration, free T3 concentrations increaseduntil reachingaplateauat 24–48
h (3.43, 3.20–3.84 vs. 1.74, 1.62–1.93 pg/ml; P  0.03) without side effects. Heart rate decreased
significantly after T3 infusion (63, 60–66 vs. 69, 60–76 beats per minute; P  0.008). Plasma nor-
adrenaline (347; 270–740 vs. 717, 413–808 pg/ml; P  0.009), N-terminal pro-B-Type natriuretic
peptide (3000, 438-4005 vs. 3940, 528-5628 pg/ml; P 0.02), and aldosterone (175, 152–229 vs. 231,
154–324 pg/ml; P 0.047) significantly decreased after T3 administration. Neurohormonal profile
did not change after placebo infusion in the control group. After synthetic L-T3 administration,
left-ventricular end-diastolic volume (142, 132–161 vs. 133, 114–158ml/m2 body surface; P 0.02)
and stroke volume (40, 34–44 vs. 35, 28–39 ml/m2 body surface; P  0.01) increased, whereas
external and intracardiac workload did not change.
Conclusions: In DC patients, short-term synthetic L-T3 replacement therapy significantly improved
neuroendocrine profile and ventricular performance. These data encourage further controlled
trials with more patients and longer periods of synthetic L-T3 administration. (J Clin Endocrinol
Metab 93: 1351–1358, 2008)
A low T3 syndrome has been documented in patients withdilated cardiomyopathy (DC); its occurrence is an inde-
pendent predictor of pooroutcome (1–5).The effect of decreased
T3 concentrations on myocyte gene expression and cardiac con-
tractility has already been documented in a model of low-T3
syndrome inwhichT3 supplementation normalized both cardiac
function and phenotype (6).
The main pathophysiological mechanism underlying low
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circulating T3 is the decreased activity of 5-monodeiodinase,
responsible for converting T4 into T3 in peripheral tissues
(1, 7).
The pathophysiological role of the progressive decrease in T3
that occurs in patients with heart failure (HF) has not yet been
established (8). It may merely be a marker of the severity of the
disease, or it could contribute to the impairment of cardiovas-
cular function. The latter hypothesis is based on the key role of
thyroid hormones on the homeostasis of the cardiovascular sys-
tem by three different routes: 1) direct effect on cardiomyocytes;
2) peripheral effects on the vasculature; and 3) modulation of
sympathetic systems (1, 9).
Although potentially promising, the usefulness of synthetic
thyroid hormone administration as a new therapeutic strategy
during evolution of HF is still debated (1, 10). In patients with
DC and low-T3 state, the short-term (a few hours) iv adminis-
tration of pharmacological doses of synthetic L-T3 increased car-
diac output (CO) and decreased systemic vascular resistance
(SVR) without changes in heart rate (HR) and arterial blood
pressure (11). Administration of synthetic L-T3 had no adverse
effects, and, in particular, no arrhythmias were observed. How-
ever, data on the effects of replacement doses of L-T3 in humans
are lacking. In addition, very little information is available on the
potential link between changes in thyroid hormone state and the
other activated neuroendocrine/proinflammatory systems dur-
ing progression of HF; however, preliminary data on humans
seem promising (12).
This study aimed to evaluate the effects of 3-d iv replacement
doses of synthetic L-T3 on clinical status, left ventricular (LV)
function, and neuroendocrine/proinflammatory profile in pa-
tients with DC and low-T3 syndrome.
Patients and Methods
Patients
A total of 500 outpatients with known post-ischemic or nonisch-
emic DC were screened. Post-ischemic DC was diagnosed by angio-
graphically proven coronary artery disease or by documented myo-
cardial infarction; nonischemic DC was diagnosed based on the
absence of coronary artery disease on angiography. Inclusion criteria
were: 1) ischemic or nonischemic dilated left ventricle, i.e. end-dia-
stolic diameter more than 56 mm and ejection fraction (EF) less than
40%, echocardiographically assessed; 2) optimized standardHFmed-
ical therapy; 3) New York Heart Association class less than III; and
3) stable thyroid function patternwith low free T3 levels confirmed on
the basis of two consecutive determinations within the last month.
Exclusion criteria were: 1) history of primary thyroid disease, 2) ami-
odarone therapy during the past 6 months, 3) concomitant severe
systemic disease, 4) complex ventricular arrhythmias, 5) severe obe-
sity (bodymass index 35 kg/m2), and 6) pregnant women or women
undergoing estro-progestinic therapy.
Based on the aforementioned criteria, a total of 445 patients was
excluded. Of the remaining 55 patients, 35 were excluded for the fol-
lowing reasons: 1) rapid, unexpected clinical worsening (n 8); 2) need
for changes in medical treatment (n  11); and 3) normalization of
thyroid pattern (n  5), refusal of hospitalization, and/or of synthetic
L-T3 infusion (n  11).
Therefore, the final population consisted of 20 patients (14 male, 6
female),with anaveragebodymass indexof28kg/m2 (range25–31), and
an average body surface area (bs) of 1.89 m2 (range 1.81–1.92) with
post-ischemic (n  12) or nonischemic (n  8) DC, randomly assigned
TABLE 1. HR, blood pressure, and rate pressure product (RPP) at baseline and after 3 d in patients treated with synthetic L-T3 or
placebo infusion
Variables
Patients treated with L-T3 Patients treated with placebo
Before L-T3 After L-T3 P value Basal After 3 d P value
HR (bpm) 69 (60–76) 63 (60–66) 0.008 67 (60–74) 70 (59–79) ns
SBP (mm Hg) 117 (111–127) 118 (113–120) ns 117 (105–128) 119 (113–128) ns
DBP (mm Hg) 68 (63–68) 70 (64–78) ns 76 (68–83) 76 (68–79) ns
MBP (mm Hg) 94 (86–102) 95 (91–96) ns 96 (86–101) 95 (92–100) ns
RPP 8281 (6384–9747) 7498 (6651–7830) ns 7702 (7226–8609) 8455 (7081–9421) ns
Data are expressed as median (25th and 75th percentiles). DBP, Diastolic blood pressure; MBP, mean blood pressure; SBP, systolic blood pressure.
TABLE 2. Effect of synthetic L-T3 infusion on cardiac rhythm
Patient
no.
No. of PACs No. of SVTs No. of PVCs No. of NSVTs
Before T3 After T3 Before T3 After T3 Before T3 After T3 Before T3 After T3
1 42 32 6 4 294 100 40 0
2 107 5 42 0 947 2047 6 0
3 1 3 1 0 177 104 0 0
4 35 24 1 2 924 66 0 0
5 5 1 5 0 227 355 0 1
6 2 6 2 1 230 135 0 0
7 45 31 2 2 353 121 48 2
8 8 2 4 0 272 426 0 1
9 50 38 7 5 739 53 0 0
10 86 4 34 0 663 1433 4 1
PAC, Premature atrial contraction; SVT, supraventricular tachyarrhythmia; PVC, premature ventricular contraction; NSVT, nonsustained ventricular tachycardia.
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to continuous 3-d iv synthetic L-T3 infusion. There were 10 patients
(mean age 72 yr, range 66–77) who underwent L-T3 infusion and com-
prised the study group. The other 10 patients (mean age 68 yr, range
64–71) underwent continuous low-rate (100 ml/d) 3-d iv infusion of
saline (placebo) solution and comprised the control group. Standardized
medical therapy for HF was optimized before the study; this remained
unchanged for at least 15 d before the study was initiated and remained
the same throughout the entire 3-d T3 infusion. Medical therapy con-
sisted of angiotensin-converting enzyme inhibitors (n  17), diuretics
(n  15), -blockers (n  16), and spironolactone (n  10 patients).
Experimental protocol
All enrolled patients were admitted to the Institute of Clinical Phys-
iology in Pisa andhospitalized toperform the studyprotocol.All patients
gave informed consent for hospitalization and L-T3 infusion. The study
was approved by the local ethics review committee and conformed to the
principles outlined in the Declaration of Helsinki. Synthetic L-T3 was
continuously infused (initial dose 20g/m2bsddiluted in 100ml saline);
we used this dosage, which is slightly higher than the measured T3 pro-
duction rate in normal humans (16 3 g/m2 bsd, mean SD) (13), to
restore normal T3 levels as rapidly as possible while avoiding potential
side effects. Starting on the first day after the beginning of infusion, on
the basis of measured T3 levels, the dose was adjusted to maintain T3
circulating levels within the normal range (see Thyroid function pattern
throughout L-T3 infusion). Clinical signs and symptoms, bio-humoral
profile, and cardiac magnetic resonance (CMR) were evaluated at base-
line and at the end of L-T3 infusion. Continuous electrocardiographic
monitoring was maintained during the entire L-T3 infusion period to
detect arrhythmias. Systolic/diastolic andmean blood pressure aswell as
HR were measured five times per day; the reported values of these pa-
rameters at baseline and after T3/placebo administration (see Results)
represent the average value of the measures. Rate pressure product was
calculated as the product between HR and systolic blood pressure.
Neuroendocrine and proinflammatory bio-humoral profile
Basal blood samples were taken at 0800 h from an antecubital vein
after a 30-min rest in supine position. Plasma N-terminal pro-brain na-
triuretic peptide (NT-proBNP) was measured with a fully automated
“sandwich” electrochemiluminescence method using an Elecsys 2010
analyzer (Roche Diagnostics, Basel, Switzerland), as previously de-
scribed (14). The low detection limit of the NT-proBNP assay was 4.2
pg/ml (0.50 pmol/liter), whereas the functional sensitivity was 22 pg/ml
(2.60 pmol/liter). Plasma renin activity (PRA) (ng/mlh) and aldosterone
(pg/ml) were measured by RIA (Dia Sorin S.r.l, Saluggia, Italy); for the
assay, blood samples were immediately put into ice-chilled tubes con-
taining EDTA, and then plasma was rapidly separated by centrifugation
at 4 C and frozen at 20 C (15). Serum TSH, free T3, and free T4 were
measured using an AIA 21 analyzer (Eurogenetics-Tosho, Turin, Italy).
The reference intervals for our laboratory were: free T3, 2.1–4.2 pg/ml
(3.4–6.5 pmol/liter); free T4, 7.1–18.5 pg/ml (9.2–24 pmol/liter); and
TSH, 0.30–3.80 IU/ml. Measured functional sensitivity for the TSH
assay was 0.12 IU/ml. For the measurement of plasma norepinephrine
(pg/ml),we used theHPLCmethod as previously described in detail (15).
Levels of IL-6 (pg/ml) were measured by a high-sensitivity ELISA tech-
nique (Diaclone Research, Besanc¸on, France).
Assessment of cardiac morphology and function
CMR imaging was performed with a 1.5 T Signa Excite Scanner (GE
Medical System, Waukesha, Wisconsin) using an eight-element phased
array cardiac receiver coil. To evaluate LV function, images were ac-
quired in short axis views, fromthemitral annulus to the ventricular apex
(thickness 8 mm, no spacing) using a breath-hold gradient-echo pulse
sequence triggered to electrocardiogram. For each image the myocar-
dium was defined by manually tracing the endocardium to assess end-
diastolic volume (EDV) (ml/m2 bs), end-systolic volume (ESV) (ml/m2
bs), stroke volume (SV) (ml/m2 bs), and EF (%). CO (liter/min) was
obtained as the product of SV and HR. SVR (dyne/sec  cm) was com-
puted as the mean arterial blood pressure divided by CO. Internal and
external cardiac works were calculated as follows: internal cardiac
work  ESV  HR  (systolic blood pressure/2); and external cardiac
work  SV  HR  mean blood pressure. Total cardiac work was
calculated as the sum of the internal and external cardiac work.
Statistical analysis
All variables are expressed as median plus 25th and 75th percentile,
unless otherwise indicated. Continuous data were analyzed by the non-
parametric Wilcoxon test. A P value less than 0.05 was considered sta-
tistically significant.ANOVAandpost hoc comparison tests for repeated
measures were performed with the Friedman test and Bonferroni ad-
justed Wilcoxon test to assess the differences of thyroid hormones and
TSH circulating levels during the 3-d L-T3 and placebo infusion. All




The main clinical characteristics of patients are shown in Ta-
ble 1. Plasma protein and albumin levels before L-T3 infusion
were normal (6.9, 6.4–7.2 g/dl, and 4.2, 3.1–6.2 g/dl, respec-
tively). Synthetic L-T3 infusion was well tolerated, and no side
effectswere reported.HRdecreased significantly,whereas blood
pressure and body weight remained unchanged. Continuous
electrocardiographic monitoring showed no increase either in
FIG. 1. Free T3 levels in patients treated with L-T3 (upper panel) and in patients
treated with placebo (lower panel).
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the number of ventricular premature beats (Table 2) or in the
appearance of ischemic episodes. QT intervals did not change
during L-T3 infusion [before T3 437, 429–477 msec vs. after T3
439, 413–478; P  not significant (ns)].
Thyroid function pattern throughout L-T3 infusion
At baseline all patients showed a typical low-T3 syndrome
with freeT3 plasma levels lower than the limit of reference range.
After starting T3 replacement iv therapy, free T3 concentrations
rapidly increased until reaching the upper level of the physio-
logical range, then remained stable throughout the entire infu-
sion time (ANOVAP 0.001) (Fig. 1). Starting from the second
day of infusion, the mean dose of administered T3 was 1.10 
0.11 g (mean  SD) per hour (range 0.8–1.2), which corre-
sponds to 24.2 g/d (range 19.2–28.8), i.e. 13.4 g/m2 bsd, on
average. A typical example of the adjustment of L-T3 infusion
rate in a patient with elevated FT3 concentrations after the first
day of administration is reported in Fig. 2. During treatment
there was a concomitant decrease in free T4 and even more in
TSH levels (ANOVA P 0.001 for TSH), although the concen-
trationsof bothhormones still remainedwithin thenormal range
(Fig. 3). In the placebo-treated patients, no significant change




Synthetic L-T3 infusion did not induce any significant change
in the main routine laboratory variables. At the end of T3 infu-
sion, there was a significant decrease in noradrenaline, NT-
proBNP, and aldosterone plasma levels (Fig. 4), whereas PRA
and IL-6 remained unchanged. Neurohormonal profile did not
change after placebo infusion in the control group.
Cardiac function
End-diastolic LV volume and SV increased significantly,
whereasEF,CO,SVR, external, internal, and total cardiacwork-
load did not change (Table 3).
Discussion
In our study we assessed the effects of the iv infusion of replace-
ment doses of L-T3 on cardiac function and on the activated
neuroendocrine system in patients with stable ischemic or non-
ischemic LV dysfunction and low-T3 syndrome. The L-T3 infu-
sion regimen adopted rapidly restoredT3 levels towithin normal
rangeandwasassociatedwitha significantdecrease inTSHlevel,
which still remained, however, in the normal range. A similar
TSH pattern was observed in the study byMoruzzi et al. (16), in
which a replacement dose of L-T4, i.e. 0.1 mg/d, was used.
Our main finding was that L-T3 infusion induced a positive
cardiac and neuroendocrine resetting characterized by improved
SV of the left ventricle and deactivation of the neuroendocrine
profile, resulting from the significant reduction in vasoconstric-
tor/sodium retaining noradrenaline, aldosterone, and in the
counterpart NT-proBNP plasma levels. The protocol we
adopted for synthetic L-T3 administration offers two main ad-
vantages: 1) constant infusionof substitutivedosesof L-T3makes
it possible to rapidly establish stable T3 levels within the phys-
iological range (Fig. 1), which is at variance with multiple bolus
injections or an oral regimen; and 2) constant infusion of sub-
stitutive doses of L-T3 is more effective in promoting nuclear
action of T3 and T3-mediated transcription in the myocardium
when compared with multiple bolus injections (14) or to an oral
regimen (17–19). However, previous studies on euthyroid pa-
tients with DC showed that short- and medium-term treatment
FIG. 2. A typical example of adjustment of synthetic L-T3 infusion rate throughout the 3-d experimental protocol.
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with 0.1 mg/d synthetic L-T4 increased CO and reduced SVR in
the absence of significant changes in HR and catecholamine cir-
culating levels (16). A similar hemodynamic finding has been
shown in our previous study in patients with subclinical hypo-
thyroidism and without cardiac disease (20). In that study, SV,
EF, and CO significantly increased after synthetic L-T4 replace-
ment therapy,whereas blood pressure values did not change.On
the contrary, the absence of a decrease in SVR after T3 infusion
observed in our low-T3 cardiomyopathic patients could be re-
lated to the significant decrease in HR associated with a signif-
icant reduction in noradrenaline levels, neither documented in
any of the previous studies cited (16), thus causing an unchanged
CO despite the documented significant increase in SV.
In addition, we preferred to administer T3 instead of the pro-
hormoneT4because inaprevious studyonhypothyroidanimals,
the restoration of serum biologically active T3 by constant infu-
sion of T4 was unable to normalize all tissue levels of T3, includ-
ing themyocardium (21). This could be evenmore evident in the
presence of an impaired peripheral conversion of T4 into T3, as
observed in low-T3 syndrome.
The main novel finding of this study is the evidence for a
deactivation of the vasoconstrictor/sodium-retaining neuroen-
docrine system that occurs after L-T3 infusion,withNT-proBNP,
noradrenaline, and aldosterone all decreasing significantlywhen
compared with baseline values and with corresponding hor-
monal levels after placebo infusion. The neuroendocrine rear-
rangement may be interpreted as an indirect rather than direct
T3-mediated action, very likely linked to the improved cardiac
performance as documented by increased LV SV. In fact, T3“per
se” is able to increase rather than decrease catecholamines, BNP,
and aldosterone release. This effect is mediated by promoting
BNP gene transcription (22) or by regulating the rate of tran-
scription of the -1-adrenergic receptor gene (23). Accordingly,
increased and decreased NT-proBNP levels have been observed
in patients with hyperthyroidism or hypothyroidism, respec-
tively (24), and parallel changes in the levels of catecholamine
and catecholaminemetabolites have been shown in cardiacmus-
cle of rats with thyroid disorders (25). Similarly, decreased al-
dosterone circulating levels have been observed in hypothyroid
patients treated with synthetic thyroid hormones (26). Further
evidence in favor of an indirect positive effect of T3 on neuroen-
docrine resetting is the observation of a decreased HR. Interest-
ingly, the improvement in cardiac performance induced by T3
did not correspond to increased myocardial oxygen consump-
tion, as indirectly estimated by calculation of the rate pressure
product as well as total cardiac work.
FIG. 3. Free thyroid hormones (left panels) and TSH circulating levels (right panels) before and during L-T3 treatment.
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Deactivation of the neuroendocrine system is a crucial goal
in the therapeutic management of HF. The potential clinical
relevance of T3-induced neuroendocrine deactivation in pa-
tients with LV dysfunction is clearly deducible from an anal-
ysis of reported data in the literature showing highly beneficial
effects of aldosterone and-adrenergic antagonists in terms of
survival, rate of hospitalization, symptoms, cardiac remodel-
ing, and performance (27). Indeed, after L-T3 administration,
in addition to neuroendocrine deactivation, we found a par-
allel increase in SV and EDV in the absence of any significant
change in LV EF. The increased EDV can be considered an
expression of the recruitment of residual ventricular filling
reserve, which is a fundamental compensatory mechanism for
maintaining CO in patients with HF (28). This finding may
result from the positive effects of biologically active T3 on
diastolic relaxation secondary to the increase in calcium AT-
Pase of the sarcoplasmic reticulum pump and to the inhibition
of its counter-regulatory phospholamban (10). Studies have
also shown an improved cardiac function and LV remodeling
after replacement doses of L-T3 (29). Future studies are needed
to clarify whether the observed positive acute changes in terms
of both neuroendocrine profile and hemodynamics will be
maintained during chronic L-T3 administration.
Limitations of the study
The study’s main limitation was the small number of pa-
tients. Therefore, results regarding the potential safety of L-T3
administration cannot be considered conclusive; another lim-
itation is that our results cannot be extended to all patients
with HF because we enrolled only highly selected and clini-
cally stable patients with LV dysfunction and low-T3 syn-
drome. The complexity and high cost of the protocol, includ-
ing hospitalization and CMR, along with the multiplicity of
inclusion and exclusion criteria adopted were the main rea-
sons for the low number of patients finally enrolled for L-T3
administration. Another limitation of the study was the lack
of assessment of the effects of synthetic L-T3 on the diastolic
function of the left ventricle. However, previous studies have
clearly shown the improvement in diastolic function induced
by synthetic thyroid hormone administration (30, 31). An-
other limitation was that the potential total body catabolic
effects of T3 were determined only indirectly by assessing
FIG. 4. Aldosterone, noradrenaline, NT-proBNP, PRA, and IL-6 levels in patients treated with L-T3 and in patients treated with placebo.
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blood urea nitrogen levels, and not directly by calorimetry.
However, in this context it has already been shown that an
increased catabolic rate occurs not only when circulating T3
levels are kept within normal range, but also during supra-
physiological L-T3 administration (10), when circulating T3
exceeds the upper limit of the reference interval.
Conclusions
Altogether, our data indicate that short-term administration
of substitutive doses of synthetic L-T3 state reduces activation of
the neuroendocrine system and improves LV SV in patients with
ventricular dysfunction and low-T3 syndrome. Future studies
will clarify whether this approach may truly be considered a
novel tool in the therapeutic strategies for managing cardiac
failure.
Acknowledgments
We thank Laura Mazza for her secretarial assistance.
Address all correspondence and requests for reprints to: Giorgio Ier-
vasi, M.D., Clinical Physiology Institute, Consiglio Nazionale delle
Ricerche, Via Moruzzi 1 Localita` la Fontina, 56124 Pisa, Italy. E-mail:
iervasi@ifc.cnr.it.
Disclosure Statement: The authors have nothing to disclose.
References
1. Klein I, Ojamaa K 2001 Mechanism of disease: thyroid hormone and the
cardiovascular system. N Engl J Med 344:501–509
2. Hamilton MA, Stevenson LW, Luu M, Walden JA 1990 Altered thyroid hor-
mone metabolism in advanced heart failure. J Am Coll Cardiol 16:91–95
3. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, ScarlattiniM, L’Abbate A,
Donato L 2003 Low-T3 syndrome: a strong prognostic predictor of death in
patients with heart disease. Circulation 107:708–713
4. Kozdag G, Ural D, Vural A, Agacdiken A, Kahraman G, Sahin T, Ural E,
Komsuoglu B 2005 Relation between free triiodothyronine/free thyroxine ra-
tio, echocardiographic parameters and mortality in dilated cardiomyopathy.
Eur J Heart Fail 7:113–118
5. Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G 2005 Tri-
iodothyronine levels for risk stratification of patients with chronic heart fail-
ure. Am J Med 118:132–136
6. KatzeffHL, Powell SR,OjamaaK1997Alterations in cardiac contractility and
gene expression during low-T3 syndrome: prevention with T3. Am J Physiol
273(5 Pt 1):E951–E956
7. Utiger RD 1995 Altered thyroid function in nonthyroidal illness and surgery:
to treat or not to treat? N Engl J Med 333:1562–1563
8. Utiger RD 2005 Commentary: T3 levels for risk stratification of patients with
chronic heart failure. Clinical Thyroidology 17:16
9. Kahaly GJ, DillmannWH 2005 Thyroid hormone action in the heart. Endocr
Rev 26:704–728
10. DillmannWH, Barrieux A, Shanker R 1989 Influence of thyroid hormone on
myosinheavy chainmRNAandothermessengerRNAs in the rat heart. Endocr
Res 15:565–577
11. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child
JS, Chopra IJ,Moriguchi JD, Hage A 1998 Safety and hemodynamic effects of
intravenous triiodothyronine in advanced congestive heart failure. Am J Car-
diol 81:443–447
12. Pingitore A, Iervasi G, Barison A, Prontera C, Pratali L, Emdin M, Giannessi
D, Neglia D 2006 Early activation of an altered thyroid hormone profile in
asymptomatic or mildly symptomatic idiopathic left ventricular dysfunction.
J Card Fail 12:520–526
13. PiloA, IervasiG,VitekF, FerdeghiniM,CazzuolaF,BianchiR1990Thyroidal
and peripheral production of 3,5,3-triiodothyronine in humans bymulticom-
partmental analysis. Am J Physiol 258(4 Pt 1):E715–E726
14. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A 2004
Analytical performance and diagnostic accuracy of a fully-automated electro-
chemiluminescent assay for the N-terminal fragment of the pro-peptide of
brain natriuretic peptide in patients with cardiomyopathy: comparison with
immunoradiometric assay methods for brain natriuretic peptide and atrial
natriuretic peptide. Clin Chem Lab Med 42:37–44
15. EmdinM, Passino C, Prontera C, Iervasi A, Ripoli A,Masini S, Zucchelli GC,
Clerico A 2004 Cardiac natriuretic hormones, neuro-hormones, thyroid hor-
mones and cytokines in normal subjects and patients with heart failure. Clin
Chem Lab Med 42:627–636
16. Moruzzi P, Doria E, Agostoni PA 1996 Medium-term effectiveness of L-thy-
roxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101:461–
467
17. Danzi S, Dubon P, Klein I 2005 Effect of serum triiodothyronine on regulation
of cardiac gene expression: role of histone acetylation.Am J PhysiolHeartCirc
Physiol 289:H1506–H1511
18. Saberi M, Utiger RD 1974 Serum thyroid hormone and thyrotropin concen-
trations during thyroxine and triiodothyronine therapy. J Clin Endocrinol
Metab 39:923–927
19. Danzi S, Ojamaa K, Klein I 2003 Triiodothyronine-mediated myosin heavy
chain gene transcription in the heart. Am J Physiol Heart Circ Physiol 284:
H2255–H2262
20. Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi
D, LombardiM, L’Abbate A, Iervasi G 2005Does subclinical hypothyroidism
TABLE 3. CMR parameters at baseline and after 3 d in patients treated with synthetic L-T3 or placebo infusion
Parameters
Patients treated with L-T3 Patients treated with placebo
Before L-T3 After L-T3
P value before
L-T3 vs. after L-T3 Basal
P value before
L-T3 vs. basal
LV EDV (ml/m2 bs) 133 (114–158) 142 (132–161) 0.02 130 (117–153) ns
LV ESV (ml/m2 bs) 103 (84–127) 108 (89–124) ns 91 (86–115) ns
LV SV (ml/m2 bs) 35 (28–39) 40 (34–44) 0.01 36 (29–48) ns
CO (liter/min) 4.1 (3.3–5.4) 4.8 (3.4–5.4) ns 4.7 (4.0–5.3) ns
CI (liter/m2 bsmin) 2.2 (1.7–2.8) 2.5 (1.9–2.7) ns 2.5 (2.1–2.9) ns
LV EF (%) 25 (18–32) 28 (22–32) ns 27 (23–41) ns
SVR (dyne/sec cm) 2.07 (1.92–3.13) 2.10 (1.87–2.48) ns 2.03 (1.86–2.36) ns
Elastance 1.36 (0.93–1.63) 1.27 (0.91–1.36) ns 1.32 (0.97–2.14) ns
External cardiac work
(mlmmHg bpm)
201,226 (161,084–3,002,307) 226,519 (169,276–266,388) ns 253,950 (190,929–306,180) ns
Internal cardiac work
(ml bpmmmHg/2)
401,849 (348,910–534,505) 396,885 (343,080–473,613) ns 360,260 (314,153–440,763) ns
Total cardiac work 626,859 (492,291–787,522) 592,085 (540,060–756,684) ns 599,945 (538,645–748,639) ns
Data are expressed as median (25th and 75th percentiles). bpm, Beats per minute; CI, cardiac index.
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